#Novamind news update#
#Novamind news series#

Novamind has begun construction on three of the New Clinics and leased a fourth additional property. The expanded capacity from the New Clinics is forecasted to increase Novamind's patient volume from 20,000 client visits recorded in 2020 to approximately 65,000 client visits anticipated in 2021, a 325% increase. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ('Novamind' or the 'Company'), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it will open four new Cedar Psychiatry clinics (the 'New Clinics'), doubling its network to eight total locations. TORONTO, ON / ACCESSWIRE / / Novamind Inc.

#Novamind news update#

The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.New clinics represent the first phase of Novamind's national expansion strategy Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind expects to share further details relating to the Strategic Investment as they become available when confidentiality restrictions are lifted. The Strategic Investment leverages Novamind's expertise in patient recruitment and patient management for the Investee's development of novel treatments for neuropsychiatric disorders.

#Novamind news series#

Novamind's Strategic Investment represents a minority equity investment in the Investee, part of a Series A financing led by Apeiron Investment Group pursuant to which the Investee raised aggregate gross proceeds of US$25,000,000.

The Investee operates a drug discovery and development business focused on neuropsychiatric disorders. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ('Novamind' or the 'Company'), a leading mental health company specialized in psychedelic medicine, announces that it has made a strategic investment of US$1,000,000 (the 'Strategic Investment') in a stealth mode drug development company based in the United States (the 'Investee'). TORONTO, ON / ACCESSWIRE / J/ Novamind Inc.